Work

Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7518

Authors: Paul M. Barr, Stephen Douglas Smith, Mark J. Roschewski, Susan Mary O'Brien, Jeff Porter Sharman, Jason M. Melear, Ahmed M. Hamdy, Raquel Izumi, J. Greg Slatter, Nataliya Chernyukhin, Elena Bibikova, Ming Yin, Tianling Chen, Stephen Edward Forbes Spurgeon

Institutions: University of Rochester Medicine, University of Rochester, University of Washington, Fred Hutch Cancer Center, National Cancer Institute, University of California, Irvine, Willamette Valley Cancer Institute and Research Center, Texas Oncology, OHSU Knight Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891564385

Cites:

Cited by: 6

Related to: 10